Share Price and Basic Stock Data
Last Updated: January 19, 2026, 9:19 pm
| PEG Ratio | -1.39 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kwality Pharmaceuticals Ltd operates within the competitive pharmaceuticals sector in India, showcasing a notable trajectory in its revenue generation. The company’s sales reported for the financial year ending March 2023 stood at ₹251 Cr, a decline from ₹456 Cr in the previous year. However, the trailing twelve months (TTM) sales reached ₹423 Cr, indicating a recovery trend. The quarterly sales figures also reveal a positive momentum, with sales increasing from ₹56 Cr in September 2022 to ₹70 Cr by September 2023. Notably, the company is projected to reach ₹370 Cr in sales for FY 2025. This consistent upward movement in sales, particularly through the latter half of 2023, positions Kwality Pharmaceuticals for potential growth as it capitalizes on market demand and operational efficiencies.
Profitability and Efficiency Metrics
Kwality Pharmaceuticals has demonstrated a solid performance in profitability metrics, with a reported operating profit margin (OPM) of 23% as of September 2023. The operating profit for the same quarter was ₹15 Cr, reflecting a stable operational performance amidst fluctuating sales. The net profit for the quarter stood at ₹6 Cr, translating to an earnings per share (EPS) of ₹6.03. The company has maintained a return on equity (ROE) of 16.2% and a return on capital employed (ROCE) of 18.2%, both of which are favorable against industry averages. However, the cash conversion cycle (CCC) of 209 days indicates room for improvement in operational efficiency, as typical industry standards suggest a lower CCC for enhanced liquidity. Overall, Kwality Pharmaceuticals’ profitability metrics, combined with effective cost management, highlight its operational resilience.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kwality Pharmaceuticals reflects a robust financial position, with total assets recorded at ₹481 Cr as of September 2025. The company’s reserves have increased to ₹282 Cr, showcasing a strong retention of earnings to support future growth. With borrowings at ₹110 Cr, the long-term debt-to-equity ratio stands at a low 0.05, indicating a conservative approach to leveraging. Additionally, the interest coverage ratio (ICR) of 8.33x suggests that the company comfortably meets its interest obligations. Financial ratios such as the price-to-book value (P/BV) of 3.43x and the current ratio of 1.67x further underscore the company’s solid liquidity position. Overall, Kwality Pharmaceuticals exhibits a healthy balance sheet, which is essential for sustaining operations and pursuing strategic initiatives.
Shareholding Pattern and Investor Confidence
The shareholding structure of Kwality Pharmaceuticals reveals a stable promoter holding of 54.82%, reflecting strong management confidence in the company’s prospects. The public shareholding stands at 44.83%, with a notable increase in the number of shareholders, which rose to 11,595 by September 2025. However, the presence of Foreign Institutional Investors (FIIs) remains absent, and Domestic Institutional Investors (DIIs) hold only 0.33%, suggesting limited institutional interest. This aspect may indicate a cautious sentiment among institutional investors regarding the company’s growth trajectory. Nevertheless, the consistent promoter stake and increasing public interest may provide a buffer against market volatility, fostering a sense of stability among retail investors.
Outlook, Risks, and Final Insight
The outlook for Kwality Pharmaceuticals appears cautiously optimistic, driven by improving revenue trends and profitability metrics. However, the company faces potential risks, including its high cash conversion cycle of 209 days, which could strain liquidity if not addressed. Additionally, the fluctuating net profit margins, particularly the decline in FY 2023, highlight the need for stringent cost controls. On the other hand, the strong balance sheet and increasing shareholder base present significant strengths. If Kwality Pharmaceuticals can effectively streamline its operations and enhance market penetration, it stands to benefit from the growing demand in the pharmaceutical sector. The company’s ability to navigate these risks while capitalizing on its strengths will be pivotal in determining its future trajectory and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 205/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,920 Cr. | 360 | 479/192 | 81.2 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.6 Cr. | 45.3 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.7 Cr. | 39.4 | 41.0/17.0 | 137 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,907.60 Cr | 1,108.76 | 52.02 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 56 | 69 | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 |
| Expenses | 40 | 41 | 57 | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 |
| Operating Profit | 16 | 15 | 12 | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 |
| OPM % | 28% | 27% | 17% | 20% | 22% | 21% | 23% | 22% | 22% | 21% | 22% | 22% | 23% |
| Other Income | 1 | 0 | -15 | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 |
| Interest | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 11 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 |
| Tax % | 20% | 28% | -24% | 25% | 24% | 21% | 28% | 25% | 33% | 25% | 24% | 30% | 23% |
| Net Profit | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 |
| EPS in Rs | 8.72 | 6.97 | -7.09 | 5.25 | 6.03 | 7.42 | 4.34 | 8.07 | 8.18 | 8.23 | 13.97 | 11.50 | 13.61 |
Last Updated: December 30, 2025, 5:05 am
Below is a detailed analysis of the quarterly data for Kwality Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 111.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 111.00 Cr..
- For Expenses, as of Sep 2025, the value is 86.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 87.00 Cr. (Jun 2025) to 86.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Jun 2025) to 23.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Jun 2025) to 18.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Jun 2025) to 23.00%, marking a decrease of 7.00%.
- For Net Profit, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 14.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 13.61. The value appears strong and on an upward trend. It has increased from 11.50 (Jun 2025) to 13.61, marking an increase of 2.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:04 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 307 | 370 | 423 |
| Expenses | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 241 | 290 | 330 |
| Operating Profit | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 67 | 80 | 93 |
| OPM % | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 22% |
| Other Income | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 3 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 10 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 19 |
| Profit before tax | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 31 | 54 | 66 |
| Tax % | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | 24% | 26% | |
| Net Profit | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 49 |
| EPS in Rs | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 23.11 | 38.44 | 47.31 |
| Dividend Payout % | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% | 66.67% | 60.00% | 0.00% | 87.50% | 700.00% | -84.17% | 26.32% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% | 16.67% | -6.67% | -60.00% | 87.50% | 612.50% | -784.17% | 110.48% | 40.35% |
Kwality Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 22% |
| 3 Years: | -7% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 37% |
| 3 Years: | -31% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 73% |
| 3 Years: | 34% |
| 1 Year: | 19% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 28% |
| 3 Years: | 15% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 9:25 am
Balance Sheet
Last Updated: January 7, 2026, 3:59 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 216 | 255 | 282 |
| Borrowings | 6 | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 98 | 112 | 110 |
| Other Liabilities | 12 | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 74 | 72 | 79 |
| Total Liabilities | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 481 |
| Fixed Assets | 11 | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 138 | 144 | 143 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 0 |
| Investments | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 | 4 | 4 |
| Other Assets | 21 | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 256 | 303 | 335 |
| Total Assets | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 481 |
Below is a detailed analysis of the balance sheet data for Kwality Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 255.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 27.00 Cr..
- For Borrowings, as of Sep 2025, the value is 110.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 112.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 79.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 481.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 451.00 Cr. (Mar 2025) to 481.00 Cr., marking an increase of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 143.00 Cr.. The value appears to be declining and may need further review. It has decreased from 144.00 Cr. (Mar 2025) to 143.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Other Assets, as of Sep 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 303.00 Cr. (Mar 2025) to 335.00 Cr., marking an increase of 32.00 Cr..
- For Total Assets, as of Sep 2025, the value is 481.00 Cr.. The value appears strong and on an upward trend. It has increased from 451.00 Cr. (Mar 2025) to 481.00 Cr., marking an increase of 30.00 Cr..
Notably, the Reserves (282.00 Cr.) exceed the Borrowings (110.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -4.00 | -7.00 | -10.00 | -14.00 | -13.00 | -21.00 | -12.00 | 118.00 | -29.00 | -31.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 | 138 | 154 |
| Inventory Days | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 |
| Days Payable | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 | 106 | 112 |
| Cash Conversion Cycle | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 | 219 | 209 |
| Working Capital Days | 60 | 35 | 41 | 21 | 19 | 21 | 43 | 25 | 62 | 120 | 103 | 100 |
| ROCE % | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% | 16% | 18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Diluted EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Cash EPS (Rs.) | 55.99 | 41.61 | 33.00 | 125.89 | 20.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 253.70 | 213.74 | 191.08 | 172.50 | 56.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 254.47 | 214.51 | 191.85 | 173.27 | 57.68 |
| Revenue From Operations / Share (Rs.) | 356.77 | 296.03 | 241.93 | 439.64 | 252.51 |
| PBDIT / Share (Rs.) | 79.32 | 65.67 | 60.79 | 168.82 | 29.33 |
| PBIT / Share (Rs.) | 61.70 | 46.82 | 46.38 | 158.52 | 23.07 |
| PBT / Share (Rs.) | 52.18 | 29.97 | 24.65 | 155.71 | 20.50 |
| Net Profit / Share (Rs.) | 38.36 | 22.76 | 18.58 | 115.59 | 14.35 |
| NP After MI And SOA / Share (Rs.) | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
| PBDIT Margin (%) | 22.23 | 22.18 | 25.12 | 38.39 | 11.61 |
| PBIT Margin (%) | 17.29 | 15.81 | 19.16 | 36.05 | 9.13 |
| PBT Margin (%) | 14.62 | 10.12 | 10.18 | 35.41 | 8.11 |
| Net Profit Margin (%) | 10.75 | 7.68 | 7.68 | 26.29 | 5.68 |
| NP After MI And SOA Margin (%) | 10.76 | 7.74 | 7.71 | 26.30 | 5.78 |
| Return on Networth / Equity (%) | 15.13 | 10.65 | 9.69 | 66.53 | 25.09 |
| Return on Capital Employeed (%) | 23.04 | 20.04 | 21.13 | 78.21 | 27.21 |
| Return On Assets (%) | 8.90 | 6.03 | 5.47 | 35.23 | 9.10 |
| Long Term Debt / Equity (X) | 0.05 | 0.08 | 0.13 | 0.11 | 0.30 |
| Total Debt / Equity (X) | 0.42 | 0.43 | 0.45 | 0.24 | 0.57 |
| Asset Turnover Ratio (%) | 0.87 | 0.82 | 0.72 | 1.79 | 1.73 |
| Current Ratio (X) | 1.67 | 1.60 | 1.65 | 1.75 | 1.35 |
| Quick Ratio (X) | 1.18 | 1.08 | 0.95 | 1.34 | 1.13 |
| Inventory Turnover Ratio (X) | 4.57 | 1.87 | 1.62 | 5.64 | 8.31 |
| Interest Coverage Ratio (X) | 8.33 | 6.56 | 10.48 | 60.05 | 11.39 |
| Interest Coverage Ratio (Post Tax) (X) | 5.03 | 3.96 | 6.95 | 42.11 | 6.57 |
| Enterprise Value (Cr.) | 997.78 | 515.35 | 400.57 | 630.81 | 85.72 |
| EV / Net Operating Revenue (X) | 2.70 | 1.68 | 1.60 | 1.38 | 0.32 |
| EV / EBITDA (X) | 12.12 | 7.56 | 6.35 | 3.60 | 2.82 |
| MarketCap / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| Price / BV (X) | 3.43 | 1.90 | 1.60 | 3.34 | 0.96 |
| Price / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| EarningsYield | 0.04 | 0.05 | 0.06 | 0.19 | 0.26 |
After reviewing the key financial ratios for Kwality Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 55.99. This value is within the healthy range. It has increased from 41.61 (Mar 24) to 55.99, marking an increase of 14.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 253.70. It has increased from 213.74 (Mar 24) to 253.70, marking an increase of 39.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 254.47. It has increased from 214.51 (Mar 24) to 254.47, marking an increase of 39.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 356.77. It has increased from 296.03 (Mar 24) to 356.77, marking an increase of 60.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 79.32. This value is within the healthy range. It has increased from 65.67 (Mar 24) to 79.32, marking an increase of 13.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 61.70. This value is within the healthy range. It has increased from 46.82 (Mar 24) to 61.70, marking an increase of 14.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 52.18. This value is within the healthy range. It has increased from 29.97 (Mar 24) to 52.18, marking an increase of 22.21.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 38.40. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 38.40, marking an increase of 15.47.
- For PBDIT Margin (%), as of Mar 25, the value is 22.23. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 22.23, marking an increase of 0.05.
- For PBIT Margin (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 15.81 (Mar 24) to 17.29, marking an increase of 1.48.
- For PBT Margin (%), as of Mar 25, the value is 14.62. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 14.62, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 10.75. This value exceeds the healthy maximum of 10. It has increased from 7.68 (Mar 24) to 10.75, marking an increase of 3.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.76. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 10.76, marking an increase of 3.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.13. This value is within the healthy range. It has increased from 10.65 (Mar 24) to 15.13, marking an increase of 4.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.04. This value is within the healthy range. It has increased from 20.04 (Mar 24) to 23.04, marking an increase of 3.00.
- For Return On Assets (%), as of Mar 25, the value is 8.90. This value is within the healthy range. It has increased from 6.03 (Mar 24) to 8.90, marking an increase of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.05, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.43 (Mar 24) to 0.42, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.82 (Mar 24) to 0.87, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.67, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 1.18, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 4.57, marking an increase of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.33. This value is within the healthy range. It has increased from 6.56 (Mar 24) to 8.33, marking an increase of 1.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.03. This value is within the healthy range. It has increased from 3.96 (Mar 24) to 5.03, marking an increase of 1.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 997.78. It has increased from 515.35 (Mar 24) to 997.78, marking an increase of 482.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 2.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 7.56 (Mar 24) to 12.12, marking an increase of 4.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For Price / BV (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 1.90 (Mar 24) to 3.43, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kwality Pharmaceuticals Ltd:
- Net Profit Margin: 10.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.13% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.03
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.7 (Industry average Stock P/E: 52.02)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nagkalan, Amritsar Punjab 143601 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Arora | Managing Director |
| Mr. Aditya Arora | WholeTime Director & CFO |
| Mrs. Anju Arora | Whole Time Director |
| Mr. Ajay Kumar Arora | Whole Time Director |
| Mrs. Geeta Arora | Whole Time Director |
| Mr. Pankaj Takkar | Independent Director |
| Mr. Kartik Kapur | Independent Director |
| Mr. Prashanth Vellanki | Independent Director |
| Mr. Ravi Shanker Singh | Independent Director |
| Mr. Vinod Kumar Sharma | Independent Director |
FAQ
What is the intrinsic value of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's intrinsic value (as of 19 January 2026) is ₹705.11 which is 34.35% lower the current market price of ₹1,074.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,114 Cr. market cap, FY2025-2026 high/low of ₹1,235/596, reserves of ₹282 Cr, and liabilities of ₹481 Cr.
What is the Market Cap of Kwality Pharmaceuticals Ltd?
The Market Cap of Kwality Pharmaceuticals Ltd is 1,114 Cr..
What is the current Stock Price of Kwality Pharmaceuticals Ltd as on 19 January 2026?
The current stock price of Kwality Pharmaceuticals Ltd as on 19 January 2026 is ₹1,074.
What is the High / Low of Kwality Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kwality Pharmaceuticals Ltd stocks is ₹1,235/596.
What is the Stock P/E of Kwality Pharmaceuticals Ltd?
The Stock P/E of Kwality Pharmaceuticals Ltd is 22.7.
What is the Book Value of Kwality Pharmaceuticals Ltd?
The Book Value of Kwality Pharmaceuticals Ltd is 281.
What is the Dividend Yield of Kwality Pharmaceuticals Ltd?
The Dividend Yield of Kwality Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Kwality Pharmaceuticals Ltd?
The ROCE of Kwality Pharmaceuticals Ltd is 18.2 %.
What is the ROE of Kwality Pharmaceuticals Ltd?
The ROE of Kwality Pharmaceuticals Ltd is 16.2 %.
What is the Face Value of Kwality Pharmaceuticals Ltd?
The Face Value of Kwality Pharmaceuticals Ltd is 10.0.